For: | Ong LT. Evidence based review of management of cardiorenal syndrome type 1. World J Methodol 2021; 11(4): 187-198 [PMID: 34322368 DOI: 10.5662/wjm.v11.i4.187] |
---|---|
URL: | https://www.wjgnet.com/2222-0682/full/v11/i4/187.htm |
Number | Citing Articles |
1 |
Wei-Chieh Lee, Po-Jui Wu, Hsiu-Yu Fang, Yen-Nan Fang, Huang-Chung Chen, Meng-Shen Tong, Pei-Hsun Sung, Chieh-Ho Lee, Wen-Jung Chung. Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure. Journal of Clinical Medicine 2022; 11(14): 3997 doi: 10.3390/jcm11143997
|
2 |
Julija G. Voicehovska, Dace Trumpika, Vladimirs V. Voicehovskis, Eva Bormane, Inara Bušmane, Anda Grigane, Eva Moreino, Aivars Lejnieks. Cardiovascular Consequences of Acute Kidney Injury: Treatment Options. Biomedicines 2023; 11(9): 2364 doi: 10.3390/biomedicines11092364
|
3 |
Chang-Shou She, Yue-Lin Deng, Guo-Qing Huang, Chao Cheng, Fang-Jie Zhang. Risk Factors and Outcome Variables of Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients. International Journal of General Medicine 2022; : 1565 doi: 10.2147/IJGM.S350361
|